Dispensed: What we saw at JPMorgan's big healthcare investor conference
Hollis Johnson/Business Insider
It's been a long, exciting albeit tiring week for the healthcare team as we made our way around San Francisco's Union Square during the J.P. Morgan Healthcare Conference. Hills were climbed, cricket tacos consumed, and healthcare discussed at length.
Many, many stories ahead from those conversations. But to start, here's what kept us busy when we weren't bustling from meeting to meeting.
New to our weekly newsletter? You can sign up here.
And Emma Court spoke to an investor who made $470 million on the deal.
A top investor who just made $470 million on buzzy biotech Loxo's $8 billion takeover told us where he might place his next bets
Emma also broke down what's going on with Bluebird Bio's plan to pay for one-time gene therapy treatments in the way you might pay for a washing machine — that is, in installments over 5 years. Bluebird laid out its plan at the conference on Tuesday.
A biotech is proposing a plan to pay for its pricey rare-disease treatment the same way you'd buy a TV or dishwasher. Here's the inside story.
Erin Brodwin covered one of the biggest stock movers of the conference, Sage Therapeutics, which revealed on Monday positive clinical trial results for its new depression drug.
Zach Tracer and I were closely tracking CVS Health's presentation at the conference — its first since its deal with Aetna went through. Now with the insurance business in tow, CVS CEO Larry Merlo laid out how it's going to shake up how we access healthcare.
Early in the week, Erin and I sat down with Verily chief medical officer Jessica Mega, who explained to us the common thread unifying all that the life sciences arm of Alphabet is working on.
We talked to the top scientist at Alphabet's life-sciences company about the common thread uniting all its seemingly random health projects — and how she plans to spend $1 billion
We covered a wide range of topics, so stay tuned for more from that interview as well.
And to end the week, Zach summed up the biggest losers coming out of the conference. Amid a mainly positive week, bad news brought down the stock price of a number of biotech companies, including Rubius Therapeutics and Sangamo Therapeutics.
Looking to digest more of what went down this week at the conference? You can find all our coverage from within and around the walls of the Westin St. Francis here.
With that, I'm going to go recover from the red-eye flight I somehow thought was a good idea. Please feel free to send recovery tips, conference observations, or reminders of what we might have missed while running up and down San Francisco to the team at email@example.com. And as always, you can find me at firstname.lastname@example.org.
via Business Insider https://read.bi/1IpULic
January 11, 2019 at 12:27PM